News | Research

Ecofect Press Release - 12 July 2019

On The July 12, 2019

The hospital-university research project "idBIORIV" led by François Vandenesch and Jérôme Lemoine, just received a funding of 5.7 million euros from the ANR.

The IdBIORIV project, led by Professor Vandenesch of CIRI (Inserm U1111, ENS Lyon, CNRS UMR5308, UCBL) and Professor Jérôme Lemoine of ISA (CNRS UMR 5280, UCBL) and coordinated by the Hospices Civils de Lyon, will develop new ultrafast diagnostic tools for bacterial infections. The goal is to detect in less than an hour the resistance and virulence of bacteria, which will bring a genuine innovative step in the treatment process. The project IdBIORIV has been awarded 5.7 million euros.

The main objectives of Lyon's three hospital-university research projects (RHU) funded by the National Research Agency (ANR) are the development of new diagnostic tools and an improvement of patient care. 15 RHU projects have been funded at the national level.

Supported by hospital researchers-practitioners (PU-PH), the three Lyon projects that have just been funded (IdBIORIV, BETPSY, and DEPGYN) will be conducted in association with the Hospices Civils de Lyon and the Léon-Bérard Center.

Focus on the RHU project « idBIORIV »

Blood stream infections (BSI) are annually responsible of hundreds of thousands deaths in the world. The time frame for identification and antimicrobial susceptibility testing of the causative agent(s) of BSI directly impacts the delay in the administration of appropriate antimicrobial therapy and, consequently, the clinical outcome of patients. MALDI-TOF mass spectrometry obviously revolutionized routine microbial identification of the standard of care procedure by drastically shortening the delay of the identification (ID) step. There is however no consensus on the tools for rapid (less than one-hour) characterization of antibiotic resistance, mainly as a consequence of either the rather limited multiplexing capability and cost per patient of molecular biology-based testing, or inaccuracy of the analysis output. These constraints explain why the definitive choice of antibiotic therapy still remains largely driven by disk-diffusion and broth microdilution antibiotic susceptibility testing (AST).

IdBIORIV project aims to overcome this limitation thanks to an innovative technology based on targeted mass spectrometry enabling both the pathogen identification and exhaustive characterization of its antibiotic resistance pattern, directly from a positive blood culture sample, and with a time-to-result of less than an hour. The project relies upon strong complementary scientific and innovation skills, between the Hospices Civils de Lyon/Centre International de Recherche en Infectiologie (infection diagnosis and epidemiology, clinical cohorts, health economy), the University of Lyon/Institut des Sciences Analytiques (innovative analytical development), and Sciex company, which is a leader in mass spectrometry solution, including In Vitro Diagnostics-granted systems in its portfolio.

Impact of IdBIORIV technology on patient’s health affected by BSI is predicted to exceed or at least be as beneficial as current molecular rapid diagnostic testing that have already shown to significantly decrease the mortality risk in recent meta-analyses but, importantly, at a significantly reduced cost for hospital institution.


Download the press release